11.06.2018 • NewsElaine BurridgeNovo Nordisk

Novo Nordisk said to plan Major Layoffs

Novo Nordisk said to plan Major Layoffs
Novo Nordisk said to plan Major Layoffs

Drugmaker Novo Nordisk plans to cut as many as 3,000 jobs and may reduce its financial guidance, according to a report in the Danish financial newspaper Borsen. The paper, citing unnamed sources with knowledge of the process, said the diabetes specialist needs to lower costs to deal with pricing pressure in the US.

Borsen said Novo’s management will present the savings plan to its board later this month and make a further-reaching announcement when it presents second-quarter results in August.  The company employs more than 42,000 people.

Analysts speaking to the US trade journal Fierce Pharma explained that, like other international drugmakers, Novo will have to offer bigger discounts to the US elder care program Medicare starting in 2019 and will have to find ways to offset the negative impact.

The bigger discounts are a provision of the budget deal passed by the US Congress last autumn, raising the pharma industry's contribution to closing the Part D "donut hole" gap in Medicare spending to 70% from 50%.

Manufacturers of drugs in high demand from the Medicare program, such as those recommended to treat diabetes or COPD, will have to bear an above-average share of the healthcare budget. In its first-quarter report, Novo forecast that the additional 20% burden could cost it 1- 2% of group’s sales in 2019.

Other drugmakers that have come under pressure to drop prices for US Medicare in the recent past are said to include Eli Lilly of the US and France’s Sanofi. According to analysts, British pharma giant GlaxoSmithKline has already offered large discounts on its COPD drug branded as Advair.

In response to pressure from US health insurers in 2016, Novo Nordisk was forced to cut prices and lay off 1,000 employees. It also reduced its long-term guidance. To boost its deteriorating share price, the Danish company is currently engaged in a share buyback scheme that will run until Aug. 6.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.